Competitive Intelligence

Week ending August 28, 2026

1. Competitive landscape snapshot (this week)

This is a baseline week: no prior-week comparison is available.

• competitor_mentions records 0 named competitor mentions across 63 responses to 9 questions.
• The only named competitor in the data is imiquimod, appearing in one explicit comparative question: “My dermatologist mentioned Valchlor vs imiquimod…” That question generated 7 answer variants, representing roughly 11% of all responses.
• No incidental competitor mentions were captured in the response-level competitors_mentioned fields. The remaining comparison prompts refer only to unnamed “alternative options” or “other topical therapies.”

The imiquimod question is therefore the clearest competitive signal, but the zero answer-level count suggests a tagging or extraction gap worth monitoring.

2. How the comparison is currently framed

The Valchlor–imiquimod comparison is framed as neutral and indication-led, rather than as a head-to-head superiority contest. The answers consistently position Valchlor as a topical chemotherapy for CTCL/mycosis fungoides and describe imiquimod as serving a different therapeutic purpose. One excerpt states that the two products are “used for different diseases/purposes,” while another says the choice is driven by “the specific diagnosis, location, and patient factors rather than a head-to-head preference.”

This is effectively a “both may be reasonable options in different contexts” framing, with no clear advantage assigned to either product. The response tags for this question do not include overclaim_language, so there is no detected competitor comparison paired with superiority language.

The broader “is Valchlor stronger?” question produced overclaim_language in 7 of 7 responses, including “stronger,” “strongest,” “superior,” and “leading.” However, no named competitor was attached to those responses. The language generally redirects the comparison toward mechanism, clinical setting, and evidence rather than explicitly favoring Valchlor or another product.

3. Movers — who’s gaining or losing ground

There are no measurable movers this week:

• No competitor has a positive or negative mention delta.
• The only available trend-history entry is this same baseline week.
• Imiquimod is a newly observed named comparator in the question set, but it cannot be classified as a rising competitor because prior-week data and answer-level mention counts are unavailable.

4. Questions worth watching

1. “My dermatologist mentioned Valchlor vs imiquimod—how do they compare in purpose and what would make someone choose one over the other?”
   Explicit, named comparison with 7 responses; currently framed neutrally.

2. “I was offered Valchlor but the pharmacist also mentioned alternative options…”
   Seven responses indicate recurring substitution/comparison interest, although no competitor is named.

3. “If a patient switches from Valchlor to another topical therapy…”
   Seven responses focus on efficacy expectations, tolerability, and practical treatment considerations—useful signals of how switching is being conceptualized.

4. “Is Valchlor ‘stronger’ than other topical therapies?”
   Seven responses and repeated superiority terminology make this a key perception question, even though no specific competitor is identified.

5. Recommended actions

1. Validate competitor extraction for the imiquimod question. The question and excerpts name imiquimod, but all response-level competitor fields are empty; resolve before using future share estimates.
2. Track the Valchlor–imiquimod comparison as a watch item next week, including whether the framing remains indication-led or shifts toward efficacy preference.
3. Monitor the generic “stronger” comparison cluster for emergence of named competitors or explicit superiority framing.
4. Treat this week as a no-shift baseline, with no evidence yet of competitor momentum or a strategic market move.